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Abstract
Background: Patients diagnosed with melanoma brain metastases have few treatment options and poor prognosis,
and improved treatment strategies for these patients require detailed understanding of the underlying pathobiology.
In this investigation we studied the vascularity and invasiveness of artificial brain metastases established from four
human melanoma cell lines.
Methods: A-07, D-12, R-18, and U-25 cells transfected with GFP were injected intracerebrally and intra-arterially in nude
mice. Moribund mice were killed and autopsied, and the brain was evaluated by fluorescence imaging or by histological
examination. Expression and secretion of factors involved in angiogenesis and invasion were assessed by quantitative
PCR, ELISA, and immunohistochemistry.
Results: The melanoma cells grew preferentially in the meninges and ventricles after intracerebral and intra-arterial
injection. Intertumor heterogeneity in the aggressiveness of meningeal tumors reflected differences in angiogenic activity
and expression of vascular endothelial growth factor A (VEGF-A) and interleukin 8 (IL-8). In contrast, growth and invasion
of the brain parenchyma relied primarily on vascular co-option. The cell lines showed different patterns of invasion from
meninges to the scull and from meninges to the brain parenchyma, and these differences were associated with
differences in expression of the matrix metalloproteinases MMP-2 and MMP-9. Furthermore, the melanoma cells
produced multiple brain lesions after intracerebral implantation by using the meningeal linings of the brain as
transport routes.
Conclusions: The melanoma cell lines showed different growth patterns in the brain, and these differences were
associated with differences in expression of the angiogenic factors VEGF-A and IL-8 and the matrix metalloproteinases
MMP-2 and MMP-9.
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Background
Malignant melanoma frequently metastasizes to the
brain and is the third most common cause of brain me-
tastases after lung and breast cancer [1]. Clinical studies
show that 30–50 % of patients with advanced-stage mel-
anoma are diagnosed with brain metastases during the
course of their disease, and the incidence of brain in-
volvement increases to 50–75 % in autopsy studies [2–5].
Current treatment options for brain metastases, including
surgical resection, stereotactic radiosurgery, and whole-
brain radiotherapy, are mostly palliative and show low effi-
cacy in melanoma patients [5, 6]. Consequently, the prog-
nosis of melanoma patients diagnosed with brain
metastases is generally poor, and many studies report a me-
dian survival of less than 6 months after diagnosis [4, 7, 8].
Development of improved treatment strategies for pa-
tients with melanoma brain metastases requires detailed
understanding of the underlying pathobiology. Most clin-
ical data are derived from retrospective studies based on
either diagnostic CT or MRI images or on histological
analysis of autopsy specimens. Such studies have shown
that multiple lesions and intratumoral hemorrhage are
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characteristic features of melanoma brain metastases and
they have identified important negative prognostic factors,
including multiple brain lesions, the presence of extracra-
nial metastases, and meningeal involvement [4, 7–10].
Studies of patient biopsies and autopsy specimens have
also suggested that diffuse infiltration and growth along
brain microvessels are common growth patterns in melan-
oma brain metastases [11, 12].
Although clinical studies have provided valuable insight
into the biology of melanoma brain metastases, preclinical
studies are required to study biological properties at a de-
tailed level and to elucidate underlying mechanisms. Mel-
anoma brain metastases have been studied preclinically by
using animal models that include spontaneous brain me-
tastases after orthotopic implantation, direct intracerebral
tumor cell implantation, intra-arterial injection of tumor
cells into the heart or the internal carotid artery, and cra-
nial window chambers [13–15]. Two different patterns of
melanoma metastases after intracarotid artery injection
have been identified. Thus, some melanoma cell lines pro-
duce lesions in the brain parenchyma whereas others pro-
duce lesions preferentially in the meninges and ventricles
[16, 17]. This site-specificity has been associated with ex-
pression of the transforming growth factor-β2 in a murine
melanoma model [18]. Data on the microscopic invasion
patterns within and between different brain compartments
are however sparse. Preclinical studies have also demon-
strated that vascularization of melanoma lesions within
the brain parenchyma occur by both angiogenesis, i.e.
sprouting of new blood vessels from pre-existing vessels,
and by vascular co-option, i.e. growth of melanoma cells
along pre-existing vessels [15, 19–21]. Angiogenesis within
the brain has been shown to depend on the vascular endo-
thelial growth factor A (VEGF-A) in melanoma as well as
lung, colon, and breast carcinoma models [19, 22, 23].
However, so far, most studies demonstrating vascular co-
option in melanoma brain metastases have used melanoma
cell lines with low expression of VEGF-A [15, 20].
The human melanoma cell lines A-07, D-12, R-18,
and U-25 have been established and extensively stud-
ied in our laboratory [24], and they have been shown
to differ substantially in angiogenic signature, angio-
genic potential, and metastatic properties when inocu-
lated orthotopically in nude mice [25, 26]. The
angiogenic potential of these melanoma cell lines is
associated with expression of VEGF-A and interleukin
8 (IL-8) [25]. Furthermore, the invasiveness of A-07
and D-12 cells in vitro has been shown to depend on
the matrix metalloproteinases MMP-2 and MMP-9
[27]. MMP-2 and MMP-9 are proteolytic enzymes
that degrade type IV collagen and other components
of the extracellular matrix, and they have been associ-
ated with tumor cell invasion, metastasis, and angio-
genesis [28].
The purpose of the study reported here was to use A-
07, D-12, R-18, and U-25 cells as models to study inter-
tumor heterogeneity in vascularity and invasiveness of
melanoma brain metastases. Artificial brain metastases
were established by intracerebral and intra-arterial injec-
tion of melanoma cells transfected with green fluores-
cent protein (GFP), and vascularization and invasion
patterns in the brain parenchyma, ventricles, meninges,
and scull bone were studied in detail by fluorescence im-
aging and histological analysis. We report that the mel-
anoma cell lines showed highly different patterns of
vascularization and invasion in the brain and, further-
more, these differences were associated with differences
in expression of the angiogenic factors VEGF-A and IL-8
and the matrix metalloproteinases MMP-2 and MMP-9.
Methods
Mice
Adult (8–10 weeks of age) female BALB/c nu/nu mice
were used as host animals. The mice were bred at our
institute and maintained under specific pathogen-free
conditions at a temperature of 22–24 °C and a humidity
of 30–50 %. The animal experiments were approved by
the Institutional Committee on Research Animal Care
and were performed according to the Interdisciplinary
Principles and Guidelines for the Use of Animals in Re-
search, Marketing, and Education (New York Academy
of Sciences, New York, NY).
Cell lines
A-07, D-12, R-18, and U-25 human melanoma cells
[24] were obtained from our frozen stock and main-
tained as monolayers in RPMI 1640 (25 mM HEPES
and L-glutamine) supplemented with 13 % bovine calf
serum, 250 μg/ml penicillin, and 50 μg/ml strepto-
mycin. The cultures were incubated at 37 °C in a hu-
midified atmosphere of 5 % CO2 in air and
subcultured twice a week. For in vivo experiments,
cells constitutively transfected with GFP were used
[29]. Cells were harvested from exponentially growing
cultures and re-suspended in Ca2+-free and Mg2+-free
Hanks’ balanced salt solution (HBSS) before injection
into animals.
Anesthesia
Intracerebral and intra-arterial injection of tumor cells
were carried out with anesthetized mice. Fentanyl cit-
rate (Janssen Pharmaceutica, Beerse, Belgium), fluani-
sone (Janssen Pharmaceutica), and midazolam
(Hoffmann-La Roche, Basel, Switzerland) were admin-
istered intraperitoneally (i.p.) in doses of 0.63 mg/kg,
20 mg/kg, and 10 mg/kg, respectively. The body core
temperature of the mice was maintained at 37–38 °C
by using a heating pad.
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Intracerebral tumor cell injection
The mice were fixed in a stereotactic apparatus (Model
900; Kopf Instruments, Tujunga, CA) for injection of
tumor cells into the right cerebral hemisphere. The in-
jection point was 2 mm anterior to the coronal and
1 mm lateral to the sagittal suture lines. A 100 μl
Hamilton syringe with a 26-gauge needle was used to in-
ject 6 μl of cell suspension at a depth of ~3 mm below
the scull. To minimize tumor cell reflux, the cells were
injected slowly and the needle was left in place for 2 min
before it was slowly retracted. Three different cell num-
bers, 5×102, 3×103, and 1×104, were included in the ex-
periments, and all results were independent of cell
number within this range. The mice were examined daily
for up to 70 days after tumor cell injection. Moribund
mice were killed and autopsied, and the brain was re-
moved for subsequent fluorescence imaging or histo-
logical analysis.
Intra-arterial tumor cell injection
A tuberculin syringe with a 26-gauge needle was used
to inject 105 cells suspended in 0.1 ml HBSS into the
left ventricle of the heart. A small air-bubble was left
in the plunger side of the syringe before injection to
facilitate blood entrance. The ribs were visualized by
a 1 cm skin incision along the sternum. The needle
was inserted vertically into the third intercostal space
1–2 mm to the left of the sternum. Spontaneous and
continuous entrance of pulsatile oxygenated blood
into the needle hub was used as an indication of
proper positioning in the left ventricle of the heart.
The cells were injected slowly over a period of ~30 s.
The mice were examined daily after tumor cell injec-
tion and moribund mice were killed and autopsied.
The brain, spinal cord, axial and inguinal lymph
nodes, lungs, kidneys, adrenal glands, pancreas, and
liver were examined by visual inspection and by fluor-
escence microscopy.
Fluorescence imaging
Imaging was performed with an inverted fluorescence
microscope equipped with a filter for green light (IX-71;
Olympus, Munich, Germany), a black-and-white CCD
camera (C4742-95, Hamamatsu Photonics, Hamamatsu,
Japan), and appropriate image acquisition software
(Wasabi, Hamamatsu Photonics). The fresh brain was im-
aged immediately after autopsy. The dorsal and ventral
surfaces of the brain as well as 3 coronal brain sections
with a thickness of approximately 2 mm were imaged at
low (x2) and high (x4-x10) magnifications.
Histological analysis
The brain was fixed in phosphate-buffered 4 % parafor-
maldehyde. Histological sections were stained with
hematoxylin and eosin (HE) by using a standard proced-
ure or immunostained by using a peroxidase-based in-
direct staining method [30]. An anti-GFP rabbit
polyclonal antibody, an anti-CD31 rabbit polyclonal anti-
body, an anti-MMP-2 rabbit polyclonal antibody, or an
anti-MMP-9 rabbit polyclonal antibody (all from Abcam,
Cambridge, United Kingdom) was used as primary anti-
body. Diaminobenzidine was used as chromogen, and
hematoxylin was used for counterstaining.
Quantitative PCR
RNA isolation, cDNA synthesis, and quantitative PCR were
performed as described in detail previously for cells in cul-
ture [29]. Briefly, gene expression was assessed by using
the RT2 Profiler PCR Array Human Angiogenesis (PAHS-
024A) from SABiosciences (Frederick, MD). Real-time
PCR was performed on an ABI 7900HT Fast Real-Time
PCR instrument (Applied Biosystems, Carlsbad, CA). Each
tumor line was run in three biological replicates. Glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) and β-
actin (ACTB) were used as normalization genes be-
cause these housekeeping genes showed stable expres-
sion across the melanoma lines studied here. Thus,
each replicate CT-value was normalized to the mean
CT-value of GAPDH and ACTB (ΔCT = CT
gene of interest
– CT
mean of GADPH and ACTB).
ELISA
Medium samples from cell cultures in exponential
growth were collected 24 h after change of medium.
Commercial ELISA kits (Quantikine; R&D Systems,
Abingdon, United Kingdom) were used according to the
manufacturer’s instructions to measure the concentra-
tions of VEGF-A, IL-8, and MMP-2 in the medium sam-
ples as described previously [25].
Statistical analysis
Statistical comparisons of data were performed by one-
way analysis of variance followed by the Student-
Neuman-Keuls test when the data complied with the
conditions of normality and equal variance, and under
other conditions by the Kruskal-Wallis one-way analysis
of variance on ranks. Statistical comparisons of survival
curves were performed using the log-rank test. Probabil-
ity values of P < 0.05 were considered significant. Statis-
tical analysis was performed with SigmaStat statistical
software (SPSS, Chicago, IL).
Results
Gene expression and secretion of proteins involved in
angiogenesis and invasion
VEGF-A gene expression and secretion rates were sig-
nificantly higher in the A-07 and U-25 lines than in the
D-12 and R-18 lines, and the A-07 line showed 2-fold
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Fig. 1 Gene expression and secretion of proteins involved in angiogenesis and invasion. Normalized gene expression and protein secretion rate
of VEGF-A (a), IL-8 (b), and MMP-2 (c) and normalized gene expression of MMP-9 (d) in the A-07, D-12, R-18, and U-25 lines, and examples of
immunohistochemical preparations of the melanoma lines stained for MMP-2 or MMP-9 (e). Gene expression was measured with quantitative
PCR and was normalized to the mean expression of two housekeeping genes (GAPDH and ACTB). Protein secretion rates were measured with
ELISA. Columns and bars represent the mean ± SEM of three (PCR) or five (ELISA) independent experiments
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higher gene expression and 8-fold higher secretion rate
than the U-25 line (Fig. 1a; P < 0.05). IL-8 gene expres-
sion and secretion rates were significantly higher in the
A-07, D-12, and U-25 lines than in the R-18 line, and
the A-07 line showed 7-fold and 13-fold higher gene ex-
pression and 2-fold and 5-fold higher secretion rate than
the D-12 and U-25 lines, respectively (Fig. 1b; P < 0.05).
The U-25 line showed 5-fold, 4-fold, and 8-fold higher
MMP-2 gene expression and 3-fold, 2.5-fold, and 22-fold
higher MMP-2 secretion rate than the A-07, D-12, and
R-18 lines, respectively (Fig. 1c; P < 0.05). The A-07 line
showed 160-fold and 470-fold higher MMP-9 gene ex-
pression than the D-12 and R-18 lines, whereas the U-25
line did not show significant expression of MMP-9
(Fig. 1d; P < 0.05). Immunohistochemistry revealed that
the U-25 line showed stronger staining for MMP-2 than
the A-07, D-12, and R-18 lines, and furthermore, A-07
was the only line that showed detectable staining for
MMP-9 (Fig. 1e).
Intracranial growth pattern following intracerebral injection
Artificial melanoma brain metastases were established
by stereotactic injection of A-07, D-12, R-18, and U-
25 cells into the right cerebral hemisphere of nude
mice (Fig. 2a). The cells were delivered intracere-
brally, and no GFP-expressing cells were detected in
the leptomeningeal lining of the brain 1 h after injec-
tion (Fig. 2b–c). All four lines showed aggressive
intracranial growth, and mice injected with A-07 or
U-25 cells showed significantly shorter survival than
mice injected with D-12 or R-18 cells (Fig. 2d; P <
0.0001). Clinical symptoms of intracranial tumor
growth differed substantially among the melanoma
lines. Mice injected with A-07 cells showed rapid
weight loss, loss of general activity, and disconnection
of scull sutures due to increased intracranial pressure.
Mice injected with U-25 cells showed moderate
weight loss, intra- and extracranial bleeding, and vis-
ible destruction of scull bone by tumor cells.
Fig. 2 Survival and macroscopic tumor growth following intracerebral injection. a Fluorescence image of the dorsal surface of the scull bone showing
the injection site (cross) located 2 mm anterior to the coronal suture (dashed arrow) and 1 mm lateral to the sagittal suture (solid arrow). b–c Low and
high magnification fluorescence images of the injection site on the dorsal surface of the brain 1 h after intracerebral injection of 104 GFP-transfected A-07
cells. d Survival versus time for mice injected with A-07, D-12, R-18, and U-25 cells. e Fraction of mice with macroscopic meningeal tumor growth at
autopsy. Columns and bars represent mean and SEM of three separate experiments, each involving ten mice. Survival curves in d are based on pooled
data from all three experiments and include 30 mice per cell line
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Fig. 3 Microscopic growth pattern following intracerebral and intra-arterial injection. a–c Microscopic tumor growth in the brain after intracerebral injection:
representative GFP fluorescence images, histological brain sections stained for GFP, and fraction of mice showing microscopic growth at the injection site
(a), in the ventricles (b), and in the leptomeninges (c). d–e Microscopic tumor growth in the brain after intra-arterial injection: representative fluorescence
images showing growth of U-25 cells in the left lateral ventricle (d) and on the ventral surface of the brain (e). High magnification images (d–e) are shown
as combined transillumination and pseudocolored fluorescence images. Arrow in d indicates corpus callosum
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Approximately 60 % of the mice injected with D-12
cells showed similar symptoms as the U-25 mice,
whereas the rest of the D-12 mice developed intracra-
nial bleeding, severe weight loss, or hind leg paralysis.
Mice injected with R-18 cells showed gradual weight
loss (cachexia) as the only clinical symptom of tumor
growth.
At autopsy, macroscopic tumor growth in the brain
parenchyma was observed in less than 5 % of the
mice, whereas macroscopic tumor growth in the men-
inges was observed in nearly all mice injected with
A-07 or U-25 cells and in a majority of mice injected
with D-12 or R-18 cells (Fig. 2e). The clinical symp-
toms observed in mice injected with A-07 or U-25
cells and a majority of mice injected with D-12 cells
could be attributed to meningeal tumor growth, and
the meningeal tumors in these mice were large
enough to cause visible compression of the right cere-
bral hemisphere. In contrast, the meningeal tumors of
mice injected with R-18 cells grew mainly horizon-
tally, and it was not clear from the macroscopic ana-
lysis whether the meningeal tumor growth caused the
clinical symptoms observed in these animals.
To study the microscopic pattern of tumor growth,
coronal brain sections were subjected to GFP-
fluorescence imaging or GFP immunohistochemistry.
Tumor growth was observed in three different loca-
tions within the brain: the injection site, the ventri-
cles, and the leptomeninges (Fig. 3a–c). Tumor
growth at the injection site and tumor growth in the
brain ventricles was observed more frequently in mice
injected with R-18 cells than in mice injected with A-
07, D-12, or U-25 cells (Fig. 3a and b). Furthermore,
microscopic analysis confirmed tumor growth in the
leptomeninges of > 90 % of the mice regardless of cell
line (Fig. 3c).
Intracranial growth pattern following intra-arterial injection
To investigate whether the melanoma cells produce a
different growth pattern when they reach the brain
via the blood stream, the cells were injected intra-
arterially into the left ventricle of the heart. All ani-
mals became moribund within 3–4 weeks due to ex-
tracranial metastases involving the liver, adrenal
glands, spinal cord, lungs, and/or lymph nodes, thus
limiting the observation time for growth in the brain.
Consequently, the brain lesions observed after intra-
arterial injection were smaller than the brain lesions
observed after intracerebral injection, but large
enough to be detected by fluorescence imaging. Simi-
lar to the intracerebral injections, the intra-arterial in-
jections produced tumor lesions associated with the
brain ventricles (Fig. 3d) and tumor lesions in the
leptomeninges (Fig. 3e).
Intertumor heterogeneity in parenchymal invasion at the
injection site
Following intracerebral injection, the R-18 cells were
more invasive than the other melanoma lines within the
brain parenchyma at the injection site. Thus, R-18 cells
showed infiltrative growth with diffuse borders between
the tumor and surrounding brain parenchyma, whereas
A-07, D-12, and U-25 cells showed well-defined lesions
with a distinct tumor border. This is illustrated in
Fig. 4a–b showing local tumor growth at the injection
site after intracerebral injection of R-18 and D-12 cells.
The R-18 cells tended to invade the surrounding brain
parenchyma by co-option of blood vessels in the tumor
periphery (Fig. 4b). Angiogenic activity at the intracere-
bral injection site was not detected for any of the melan-
oma lines.
Intertumor heterogeneity in ventricular growth and invasion
Ventricular R-18 tumors grew as well-defined lesions
within the intraventricular spaces of the brain and
showed no signs of invasion into surrounding tissues,
whereas invasion from the ventricles and into sur-
rounding tissues was observed in mice injected with
A-07, D-12, or U-25 cells. This is illustrated in
Fig. 4c–d showing tumor growth in the lateral ventri-
cles (Fig. 4c) and in the fourth ventricle (Fig. 4d) fol-
lowing intracerebral injection of R-18 and D-12 cells.
R-18 mice with ventricular growth (V+) showed sig-
nificantly shorter survival than R-18 mice without ven-
tricular growth (V-) (Fig. 4e, upper panel; P < 0.001). In
contrast, R-18 mice with macroscopic meningeal tumor
growth (M+) showed significantly longer survival than
R-18 mice without macroscopic meningeal tumor
growth (M-) (Fig. 4e, lower panel; P < 0.001), and this
was most likely a result of a lower frequency of ventricu-
lar tumor growth in mice with meningeal tumors than
in the mice without meningeal tumors (29 % vs 100 %).
The survival of R-18 mice after intracerebral injection
was therefore limited mainly by ventricular rather than
meningeal tumor growth.
Intertumor heterogeneity in meningeal vascularization
and scull bone invasion
Intracerebral injection produced meningeal A-07, U-
25, and D-12 tumors that were highly vascularized,
and intra-tumoral bleedings were frequently observed,
particularly in U-25 and D-12 mice. Evaluation of
CD31-stained histological sections revealed an in-
creased number of blood vessels within leptomenin-
geal tumors that appeared enlarged and irregular
compared to normal leptomeningeal vessels, suggest-
ing angiogenic activity (Fig. 5a–b). In contrast, menin-
geal R-18 tumors appeared less vascularized, and
angiogenic vessels were not detected in CD31-stained
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histological sections (Fig. 5c). Quantitative analysis
showed that the microvascular density was signifi-
cantly higher in leptomeningeal A-07, D-12, and U-25
tumors than in leptomeningeal R-18 tumors (Fig. 5d;
P < 0.05).
The melanoma lines showed highly different abilities
to invade and disrupt the scull bone. Fig. 5e shows a
HE-stained histological section of a meningeal U-25
tumor growing between the brain and the overlying
scull bone. The scull bone is in the process of being
invaded and disrupted by tumor cells (Fig. 5f ).
Macroscopic scull bone disruption was observed more
frequently in mice injected with U-25 cells than in
mice injected with A-07, D-12 or R-18 cells (Fig. 5g;
P < 0.05). Moreover, the differences among the cell
lines in scull bone disruption were associated with
differences in expression of MMP-2 (Fig. 5h).
Melanoma cell invasion along and across the meningeal
linings of the brain
All four melanoma lines produced multiple meningeal
lesions along the surface of the brain after intracerebral
Fig. 4 Intertumor heterogeneity in growth and invasion at the injection site and in the ventricles. a–b Low and high magnification images of
GFP-stained (a) and HE-stained (b) histological brain sections showing tumor growth at the injection site following intracerebral injection of R-18
and D-12 cells. Arrow indicates a blood vessel with co-optive tumor growth. c–d GFP-stained (c) and HE-stained (d) brain sections showing tumor growth
in the lateral (c) and fourth (d) ventricles following intracerebral injection of R-18 and D-12 cells. e Survival versus time for R-18 mice with and without
ventricular tumor growth (V+ and V-), and R-18 mice with and without macroscopic meningeal tumor growth (M+ and M-)
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injection, as illustrated in Fig. 6a. GFP immunohisto-
chemistry revealed tumor deposits on the surfaces of
multiple brain regions, including the dorsal and ven-
tral surfaces of the cerebrum and the ventral surfaces
of the midbrain and cerebellum (Fig. 6b). This growth
pattern indicated that the melanoma cells invaded
along the meningeal linings of the brain to reach dis-
tant parts of the brain surface. In mice injected with
A-07, D-12, or U-25 cells, this meningeal invasion
was followed by secondary invasion of the brain par-
enchyma, and two different invasion patterns were
observed. Invasion via the perivascular spaces of ves-
sels entering the brain was characteristic of D-12 and
U-25 cells (Fig. 6c), and single cell or multicellular
migration followed by co-option of microvessels
within the brain parenchyma was characteristic of A-
07 and D-12 cells (Fig. 6d). Combined invasion along
and across the meningeal linings of the brain resulted
in multiple brain lesions that involved brain compart-
ments far from the injection site. An example of D-
12 cells invading the cerebellum and brain stem is
shown in Fig. 6e.
Discussion
The human melanoma cell lines A-07, D-12, R-18, and
U-25 showed aggressive intracranial growth following
intracerebral implantation, and the survival of the mice
was limited by tumor growth in the meninges and ven-
tricles rather than by local tumor growth at the injection
site. A similar growth pattern was observed after intra-
arterial injection, suggesting that a preference for growth
in the meninges and ventricles was a characteristic fea-
ture of the melanoma cells. All four cell lines are estab-
lished from subcutaneous metastases [24], and the
results are thus in accordance with previous studies
showing that human melanoma cell lines derived from
non-CNS metastases produce lesions mainly in the men-
inges and ventricles after intracarotid artery injection,
whereas cell lines derived from brain metastases produce
lesion mainly in the brain parenchyma [16, 17]. In the
Fig. 5 Intertumor heterogeneity in meningeal vascularization and scull bone invasion. a–c Histological brain sections stained for CD31 to visualize
blood vessels in the leptomeninges of a normal brain (a), a leptomeningeal U-25 tumor (b), and a leptomeningeal R-18 tumor (c). d Microvascular
density in leptomeningeal tumors assessed from CD31 immunohistochemistry. Columns and bars represent mean and SEM of 4 mice. e HE-stained
coronal section through the brain and overlying scull bone ~1 mm anterior to the site of intracerebral injection of U-25 cells. f High magnification
image of area indicated in E showing scull bone disrupted by tumor growth. g Fraction of mice with macroscopic scull bone destruction at autopsy.
Columns and bars represent mean and SEM of three separate experiments, each involving 10 mice. h Fraction of mice with macroscopic scull bone
destruction versus MMP-2 gene expression assessed by quantitative PCR. Points represent melanoma cell lines. Line represents logarithmic regression
curve (y = y0 + a · ln x, R
2 = 0.93, P < 0.05)
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present study, the melanoma cells induced angiogenesis
in the meninges, whereas angiogenic activity was not de-
tected within the brain parenchyma. Blood vessels in the
brain parenchyma form a tight blood brain barrier,
whereas meningeal capillaries are lined by fenestrated
endothelium and are thus more similar to capillaries
found in most extracranial organs [16, 17]. The melan-
oma cells’ preference for growth in the meninges may
Fig. 6 Melanoma cell invasion along and across the meningeal linings of the brain. a GFP-fluorescence images of the dorsal and ventral surfaces
of the brain after intracerebral injection of D-12 cells. Arrow indicates injection site. b GFP-stained histological brain sections after intracerebral
injection of R-18 cells. GFP-expressing tumor deposits are present on the dorsal and ventral surfaces of the cerebrum (upper panel) as well as
on the ventral surface of the midbrain (middle panel) and cerebellum (lower panel). The three brain sections were obtained ~1 mm anterior,
~3 mm posterior, and ~6 mm posterior to the injection site. c–d Histological brain sections showing parenchymal invasion of U-25, A-07, and
D-12 cells. e Histological brain sections showing D-12 cells invading the cerebellum and brain stem after intracerebral injection
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therefore reflect differences between meningeal and par-
enchymal blood vessels in their susceptibility to angio-
genic factors secreted by the melanoma cells.
The aggressiveness of meningeal tumors differed sub-
stantially among the melanoma lines, and these differ-
ences were associated with differences in angiogenic
activity and in expression of VEGF-A and IL-8. Thus, A-
07, D-12, and U-25 cells grew more aggressively in the
meninges, showed higher microvascular density in lepto-
meningeal tumors, and showed higher expression and
secretion of VEGF-A and IL-8 than R-18 cells. In con-
trast, all four melanoma lines appeared to rely primarily
on vascular co-option for growth and invasion of the
brain parenchyma regardless of VEGF-A expression.
Our data thus suggest that also melanoma cells with
high expression of VEGF-A may show a co-optive and
infiltrative growth pattern within the brain. The observa-
tion time for tumor growth in the brain parenchyma
was limited by the aggressiveness of the meningeal tu-
mors and, therefore, it is possible that also parenchymal
lesions induce angiogenesis in a later growth stage. For
example, parenchymal lesions may develop regions with
hypoxic tissue during expansion, and changes in the ex-
tent of hypoxia during growth may cause dynamic
changes in the expression of angiogenic factors influen-
cing the form of vascularization, leading to vascularization
by angiogenesis in addition to co-option in large lesions.
The correlations reported here suggest that VEGF-A
and IL-8 are required for the growth of brain metastases
in our artificial metastasis models. This suggestion is in
accordance with an earlier work with the same melan-
oma lines showing that treatment of tumor-bearing mice
with neutralizing antibody against VEGF-A or IL-8 de-
creased the microvascular density and the growth rate of
the primary tumor and reduced the incidence of spon-
taneous metastases, including lymph node, pulmonary,
hepatic, and brain metastases [26]. Our suggestion is
also consistent with a study by Yano et al. [22], reporting
that VEGF-A expression is necessary but not sufficient
for production and growth of brain metastases.
The melanoma lines showed highly different invasion
patterns, and differences in invasiveness was associated
with differences in expression of MMP-2 and MMP-9.
Thus, R-18 cells invaded locally both within the brain par-
enchyma at the injection site and within the leptomenin-
ges and ventricles, but showed low ability to invade across
the barriers separating different brain compartments. In
contrast, A-07, D-12, and U-25 cells frequently invaded
the brain parenchyma from the meninges or ventricles.
The brain parenchyma and the pia mater are separated by
the glia limitan, consisting of astrocyte foot processes at-
tached to a parenchymal basal lamina [31]. MMP-2 and
MMP-9 have previously been shown to facilitate the mi-
gration of leukocytes across the glia limitans [31, 32]. In
this study, we found higher expression of MMP-2 in the
A-07, D-12, and U-25 lines than in the R-18 line, and
higher expression of MMP-9 in the A-07 line than in the
other lines. Lower expression of these matrix metallopro-
teinases could thus potentially explain the low invasive-
ness of R-18 cells across the glia limitan.
A-07, D-12, R-18, and U-25 cells growing in the
meninges also differed considerably in their ability to
invade and destruct the overlying scull bone. These
differences were not directly related to angiogenic ac-
tivity in the meninges. Thus, although A-07 and U-25
mice showed similar aggressiveness and angiogenic
activity in the meninges, the ability to invade and de-
struct the scull bone was substantially higher for U-
25 cells than for A-07 cells. Interestingly, the fraction
of mice with macroscopic scull bone destruction was
closely associated with the expression of MMP-2.
Overexpression of MMP-2 has previously been shown
to promote both brain and bone metastasis in a pre-
clinical model of breast cancer and to promote bone
absorption in a prostate cancer model [33, 34]. Our
data suggest that MMP-2 may be associated with
bone invasion also in melanoma, and this warrants
further investigations.
In a previous study, we revealed that A-07, D-12, and T-
22 melanoma cells cultured at acidic extracellular pH
show increased secretion of MMP-2 and MMP-9, en-
hanced invasiveness in vitro, and enhanced potential to
develop experimental pulmonary metastases in BALB/c
nu/nu mice [27]. Moreover, acidity-induced experimental
pulmonary metastasis was inhibited by treatment with the
general MMP inhibitor GM6001 and the general cysteine
proteinase inhibitor E-64 [27], suggesting that MMP-2
and MMP-9 are required for the development of pulmon-
ary metastases in our melanoma models. Because brain
metastases frequently originate from pulmonary metasta-
ses, it is likely that MMP-2 and MMP-9 are required for
the development of spontaneous brain metastases also.
Other members of the MMP family may also be involved
in melanoma brain metastasis; however, we have no evi-
dence from our models that MMP-1, MMP-13, or MT1-
MMP is required for metastatic growth in the brain.
Melanomas have a high tendency to produce multiple
brain lesions, and Kienast et al. have suggested that this
tendency is the result of a high motility of melanoma
cells within the brain [15]. Our data are consistent with
this suggestion, showing that melanoma cells injected
into a specific location in the right cerebral hemisphere
are able to produce multiple brain lesions involving
brain compartments far from the injection site. More-
over, our data show that the melanoma cells used the
meningeal surfaces of the brain as transport routes.
Leptomeningeal involvement has been shown to be cor-
related with an increased number of parenchymal lesions
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in a large retrospective study of patients with stage IV
melanoma [8]. Furthermore, autopsy studies have sug-
gested that the true incidence of leptomeningeal metas-
tasis may be substantially higher than the clinical
incidence [2, 3]. Consequently, efficient treatment strat-
egies for patients with melanoma brain metastases may
need to target melanoma cells in the meninges as well as
in the brain parenchyma.
New treatment strategies for patients with melanoma
brain metastases are highly needed, and antiangiogenic
therapy targeting the VEGF-A pathway has been sug-
gested as a potential strategy [35]. However, patients
who harbor brain metastases with a co-optive growth
pattern will most likely not respond to antiangiogenic
agents. Although VEGF-A-dependent angiogenesis is a
characteristic feature of malignant melanoma [36],
anti-VEGF-A therapy may have limited potential in
patients with melanoma brain metastases due to a
tendency of melanoma cells to grow by vascular co-
option in the brain despite high expression of VEGF-
A. Metastases with a co-optive growth pattern are
also more difficult to treat with surgical resection or
stereotactic radiosurgery due to the diffuse borders
between tumor and normal tissue.
Conclusions
The human melanoma cell lines A-07, D-12, R-18, and
U-25 showed characteristic patterns of vascularization
and invasion in the brain, and these differences were as-
sociated with differences in expression of the angiogenic
factors VEGF-A and IL-8 and the matrix metalloprotein-
ases MMP-2 and MMP-9. Furthermore, the melanoma
cells showed a co-optive and infiltrative growth pattern
within the brain parenchyma, and produced multiple
brain lesions after intracerebral injection by using the
meningeal linings of the brain as a route of transport.
Our study suggests that melanoma brain metastases may
grow by vascular co-option in the brain despite high ex-
pression of VEGF-A and, moreover, it suggests that effi-
cient treatment strategies for patients with melanoma
brain metastases may need to target melanoma cells
within the meninges as well as the brain parenchyma.
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